KWESST Micro Systems Engages RedChip to Lead Investor Relations Efforts

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (FSE: 62U) ("KWESST" or the "Company") is pleased to announce it engaged RedChip Companies ("RedChip") to lead its investor relations efforts.

"We are excited to work with RedChip as we enter what we believe will be a new phase of growth for our company," said David Luxton, Executive Chairman of KWESST. "After comparing the alternatives, we selected RedChip to help increase our visibility amongst investors because they have an impeccable reputation and a multi-decade track record of results. We look forward to a beneficial relationship that broadens our shareholder base and effectively communicates our exciting story to the investment community."

"KWESST is well positioned to benefit from the increase in security and defense spending underway globally," commented Dave Gentry, CEO of RedChip. "We are very pleased to have the opportunity to introduce KWESST to our vast network of investors."

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. Founded in 1992, and headquartered in Orlando, Florida, with affiliates in New York and Pittsburgh, RedChip has helped hundreds of companies achieve their capital markets goals and currently represents 70+ emerging growth companies.

RedChip's unique platform combines traditional investor relations services with multi-media marketing, including social media and email marketing, as well as a weekly TV show, the RedChip Money Report®, which airs on Bloomberg at 7 p.m. ET every Saturday. RedChip's traditional investor relations platform includes retail and institutional roadshows in major U.S. cities, press release writing, strategic counsel, management of quarterly conference calls, script writing, power-point presentation development, and more. RedChip will be paid a monthly fee of USD $15,000.

About KWESST

KWESST (TSXV: KWE) (OTCQB: KWEMF) (FSE: 62U) commercializes breakthrough next-generation tactical systems for military and security forces and personal defense. The company's current portfolio of unique proprietary offerings includes its unique non-lethal PARA OPS^TM system with application across all segments of the non-lethal market, including law enforcement and personal defence. KWESST also facilitates digitization of tactical forces with its signature TASCS system for real-time awareness and targeting information from any source (including drones) streamed directly to users' smart devices and indirect fire weapons. Other KWESST products include counter-measures against threats such as drones, lasers and electronic detection. These include: the Phantom^TM electronic battlefield deception system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations that deceive and confuse adversaries; a Battlefield Laser Detection System to counter the emerging threat of laser targeting of personnel; and, a non-kinetic system to counter the threat of tactical drones. These systems can operate stand-alone or integrate seamlessly with third-party OEM products and networked battlefield management systems such as ATAK. The Company is headquartered in Ottawa, Canada, with operations in Stafford, VA and representative offices in London, UK and Abu Dhabi, UAE.

For more information, please visit https://kwesst.com/

Contact: Steve Archambault, CFO, archambault@kwesst.com or (613) 317-3941
Jason Frame, Investor Relations: frame@kwesst.com

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation for the purpose of providing information about management's current expectations and plans relating to the future, including its prospects of winning contracts with NATO and non-NATO countries for the Company's Phantom^TMand its Laser Detection suite. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121565

News Provided by Newsfile via QuoteMedia

KWESST Emerging Tech Investing

KWE:CA

KWESST Announces Public Offering of Units in Canada

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

KWESST Micro Systems Inc. (TSXV: KWE) ("KWESST" or "the Company") announced today that it has commenced an underwritten public offering in Canada of units for gross proceeds of approximately USD$3 million (the "Offering"). Each unit (a "Unit") is comprised of one common share in the capital of KWESST (a "Share") and a common share purchase warrant (a "Warrant"). Each Warrant entitles its holder to purchase one additional common share for a period of five years from closing. PI Financial Corp. is acting as book-runner and sole underwriter in connection with the Offering.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

KWESST Publicly Files a Registration Statement with the United States Securities and Exchange Commission for a Proposed Registered Offering in the United States and Dual-Listing on the Nasdaq Capital Market

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (FSE: 62U) ("KWESST" or the "Company") announced today that it has publicly filed a registration statement on Form F-1 with the United States Securities and Exchange Commission (the "SEC") relating to a proposed public offering of common units, consisting of one common share and a warrant to purchase one common share, and pre-funded units, consisting of a pre-funded warrant to purchase one common share and a warrant to purchase one common share (the "Offering"). The number of units and price range for the proposed Offering have yet to be determined. The Offering is expected to take place after the SEC completes its review process, subject to market and other customary conditions. Contingent on the closing of the Offering, KWESST has applied to list its common shares on the Nasdaq Capital Market under the ticker symbol "KWE" and the warrants offered in the Offering under the ticker symbol "KWESW".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

KWESST Announces Grant of Stock Options

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) ("KWESST" or the "Company") announces it has awarded stock options pursuant to its Long-Term Performance Incentive Plan, to its Chief Financial Officer to purchase up to an aggregate of 100,000 common shares of the Company. The stock options are exercisable at a price of $0.205 per share and will expire on July 22, 2027.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

KWESST Micro Systems Engages RedChip to Lead Investor Relations Efforts

Latest News

Latest Press Releases

Related News

TOP STOCKS